Comparing the Efficacy of Fosnetupitant, an NK1 Receptor Antagonist in CDDP-Based Regimens, with That of Fosaprepitant and Aprepitant : A Retrospective Observational Study
Existing antiemetic therapy against emetic-risk agents across malignancies 24 h post-dose in the acute period in cisplatin (CDDP)-based regimens yields a satisfactory complete response (CR) rate of ≥90%. However, the control rate after 24 h in the delayed period is unsatisfactory. This study compared the efficacy of fosnetupitant (F-NTP), a neurokinin 1 receptor antagonist, with that of fosaprepitant (F-APR) and aprepitant (APR) in the treatment of patients with cancer at high emetic risk due to chemotherapy. In this retrospective case-control study involving patients receiving cisplatin-containing regimens and neurokinin 1 receptor antagonists, patients were divided into three groups based on prophylactic antiemetic therapy: F-NTP, F-APR, and APR. The CR rate was evaluated for each period up to 168 h and further subdivided into acute (0-24 h), delayed (24-120 h), overall (0-120 h), and beyond-delayed (120-168 h) periods. Eighty-eight patients were included in the F-NTP group, 66 in the F-APR group, and 268 in the APR group. The CR rates at 0-168 and 120-168 h after cisplatin administration were significantly higher in the F-NTP group than in the F-APR and APR groups. After adjusting for confounding factors, F-NTP use was an independent factor in the multivariate analysis. Prophylactic antiemetic therapy, including F-NTP, was effective and well-tolerated during the delayed period. The efficacy of F-NTP in managing chemotherapy-induced nausea and vomiting was superior to those of F-APR and APR during the study period.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
Biological & pharmaceutical bulletin - 47(2024), 3 vom: 25. März, Seite 692-697 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Inano, Hiroshi [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.03.2024 Date Revised 26.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1248/bpb.b23-00819 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369078101 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369078101 | ||
| 003 | DE-627 | ||
| 005 | 20240326235611.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1248/bpb.b23-00819 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1348.xml |
| 035 | |a (DE-627)NLM369078101 | ||
| 035 | |a (NLM)38417893 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Inano, Hiroshi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparing the Efficacy of Fosnetupitant, an NK1 Receptor Antagonist in CDDP-Based Regimens, with That of Fosaprepitant and Aprepitant |b A Retrospective Observational Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.03.2024 | ||
| 500 | |a Date Revised 26.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Existing antiemetic therapy against emetic-risk agents across malignancies 24 h post-dose in the acute period in cisplatin (CDDP)-based regimens yields a satisfactory complete response (CR) rate of ≥90%. However, the control rate after 24 h in the delayed period is unsatisfactory. This study compared the efficacy of fosnetupitant (F-NTP), a neurokinin 1 receptor antagonist, with that of fosaprepitant (F-APR) and aprepitant (APR) in the treatment of patients with cancer at high emetic risk due to chemotherapy. In this retrospective case-control study involving patients receiving cisplatin-containing regimens and neurokinin 1 receptor antagonists, patients were divided into three groups based on prophylactic antiemetic therapy: F-NTP, F-APR, and APR. The CR rate was evaluated for each period up to 168 h and further subdivided into acute (0-24 h), delayed (24-120 h), overall (0-120 h), and beyond-delayed (120-168 h) periods. Eighty-eight patients were included in the F-NTP group, 66 in the F-APR group, and 268 in the APR group. The CR rates at 0-168 and 120-168 h after cisplatin administration were significantly higher in the F-NTP group than in the F-APR and APR groups. After adjusting for confounding factors, F-NTP use was an independent factor in the multivariate analysis. Prophylactic antiemetic therapy, including F-NTP, was effective and well-tolerated during the delayed period. The efficacy of F-NTP in managing chemotherapy-induced nausea and vomiting was superior to those of F-APR and APR during the study period | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a aprepitant | |
| 650 | 4 | |a chemotherapy-induced nausea and vomiting | |
| 650 | 4 | |a delayed emesis | |
| 650 | 4 | |a fosaprepitant | |
| 650 | 4 | |a fosnetupitant | |
| 650 | 4 | |a neurokinin 1 receptor antagonist | |
| 650 | 7 | |a Aprepitant |2 NLM | |
| 650 | 7 | |a 1NF15YR6UY |2 NLM | |
| 650 | 7 | |a Cisplatin |2 NLM | |
| 650 | 7 | |a Q20Q21Q62J |2 NLM | |
| 650 | 7 | |a Antiemetics |2 NLM | |
| 650 | 7 | |a fosaprepitant |2 NLM | |
| 650 | 7 | |a 6L8OF9XRDC |2 NLM | |
| 650 | 7 | |a Emetics |2 NLM | |
| 650 | 7 | |a Neurokinin-1 Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Gastrointestinal Agents |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Morpholines |2 NLM | |
| 700 | 1 | |a Morimoto, Yoshihito |e verfasserin |4 aut | |
| 700 | 1 | |a Kitagawa, Kanata |e verfasserin |4 aut | |
| 700 | 1 | |a Shibuya, Akito |e verfasserin |4 aut | |
| 700 | 1 | |a Nakagomi, Kozue |e verfasserin |4 aut | |
| 700 | 1 | |a Ota, Tomohiro |e verfasserin |4 aut | |
| 700 | 1 | |a Anzo, Yuri |e verfasserin |4 aut | |
| 700 | 1 | |a Miyauchi, Rika |e verfasserin |4 aut | |
| 700 | 1 | |a Shono, Aiko |e verfasserin |4 aut | |
| 700 | 1 | |a Watanabe, Kazuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Otori, Katsuya |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biological & pharmaceutical bulletin |d 1997 |g 47(2024), 3 vom: 25. März, Seite 692-697 |w (DE-627)NLM074696084 |x 1347-5215 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2024 |g number:3 |g day:25 |g month:03 |g pages:692-697 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1248/bpb.b23-00819 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2024 |e 3 |b 25 |c 03 |h 692-697 | ||